Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University of Pittsburgh Medical Center Rehabilitation Institute | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
This is a pilot study involving a hybrid in-person + telerehabilitation intervention for rural adults with knee osteoarthritis. The primary purpose is to demonstrate feasibility and safety of the RAPTOR program, and the secondary purpose is to estimate clinical effectiveness of the RAPTOR program on participants' pain, function, and quality of life.
The purpose of the RAPTOR pilot study is to determine feasibility of a rural telerehabilitation intervention by assessing (1) attendance rate for telerehabilitation visits among participants in the pilot program; (2) participants satisfaction with the program; and (3) participant outcomes regarding pain, function, and quality of life. This pilot study will provide preliminary data to support efforts to obtain external funding for a future randomized trial comparing traditional physical therapy (PT) to the RAPTOR approach.
The primary purpose of the RAPTOR pilot study is to demonstrate feasibility and safety of the RAPTOR program in rural adults with knee osteoarthritis (KOA). The secondary purpose is to estimate clinical effectiveness of the RAPTOR program on participants' pain, function, and health-related quality of life. This will enable the investigators to determine a sample size estimate for a future trial comparing RAPTOR to a traditional face-to-face physical therapy approach in this population.
Specific Aim 1: To assess feasibility of the Rural Access to Physical Therapy for Osteoarthritis Rehabilitation (RAPTOR) program in delivering a hybrid telerehabilitation program to rural people with KOA.
Hypothesis 1: Participants in the RAPTOR program will attend at least 80% of study-related in-person and telerehabilitation visits, and will experience no serious adverse events.
Specific Aim 2: To determine preliminary clinical effectiveness of the RAPTOR program by assessing pain, physical function, and health-related quality of life via patient-reported and performance-based outcomes.
Hypothesis 2: A majority of RAPTOR participants will demonstrate clinically meaningful improvement in patient-reported pain, physical function, and/or health-related quality of life.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| RAPTOR Physical Therapy Intervention | Experimental | RAPTOR intervention: hybrid in-person + telehealth physical therapy care for rural-dwelling individuals with knee osteoarthritis |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| RAPTOR protocol: hybrid in-person + telehealth physical therapy services | Other | All participants will receive the RAPTOR intervention, which includes 2 in-person physical therapy visits and 8 telerehabilitation visits. Participants will attend an initial in-person PT evaluation to meet their provider, receive a hands-on assessment of their impairments and functional limitations, and receive instruction in an initial home exercise program. The remainder of their visits will be completed remotely, using a telerehabilitation platform. At the conclusion of care, the patient will return to the clinic for a follow-up assessment and training on their final home exercise program. |
| Measure | Description | Time Frame |
|---|---|---|
| Recruitment Target | The investigators' recruitment target is 27 participants, and this outcome will be successful upon enrollment of the 27th participant. This outcome will be used as one component of the overall summary outcome of "feasibility", which is defined as success in all 5 primary outcomes. | Through study completion, which is anticipated to take approximately 1 year. |
| Visit Attendance (75% or higher) | The percentage of physical therapy visits attended, divided by the number of scheduled visits (10) for each participant. This outcome will be successful if mean visit attendance among all participants is at least 75%. This outcome will be used as one component of the overall summary outcome of "feasibility", which is defined as success in all 5 primary outcomes. | Through study completion, which is anticipated to take approximately 1 year. |
| Telehealth Usability Questionnaire | The Telehealth Usability Questionnaire (5/7) is a self-reported questionnaire used to assess participant satisfaction with the telehealth services received. It contains 21 items, each rated on a 7-point scale ranging from "strongly disagree" (1 point) to "strongly agree" (7 points). The items are summed to create a total score ranging from 7 - 147 points, with higher numbers indicating greater usability of the telehealth services. This outcome will be successful if the average item rating across all participants is at least 5/7. This outcome will be used as one component of the overall summary outcome of "feasibility", which is defined as success in all 5 primary outcomes. | Measured at post-treatment (last visit, approximately 10 weeks after enrollment) |
| Study-Related Adverse Events / Serious Adverse Events | This outcome will be successful if there are zero study-related adverse events and serious adverse events among the 27 participants. This outcome will be used as one component of the overall summary outcome of "feasibility", which is defined as success in all 5 primary outcomes. |
| Measure | Description | Time Frame |
|---|---|---|
| Functional outcome measure: 30-second chair stand test | Measures the number of times the participant can stand up and sit down from a chair in a 30-second period. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) |
| Functional outcome measure: Timed stair climb test |
Not provided
Potential participants who meet all of the following criteria will be included:
Potential participants will be excluded if any of the following criteria apply:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Allyn Bove, DPT, PhD | University of Pittsburgh | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Pittsburgh | Pittsburgh | Pennsylvania | 15219 | United States |
Only fully deidentified data will be made available to other researchers upon request and approval by the investigators and the relevant institutional review board.
Data will be made available upon the conclusion of the study for up to seven years upon request.
Requests for data sharing must be agreed to by the investigators and the relevant institutional review board.
Not provided
Not provided
| ID | Term |
|---|---|
| D020370 | Osteoarthritis, Knee |
| D001168 | Arthritis |
| D010003 | Osteoarthritis |
| ID | Term |
|---|---|
| D007592 | Joint Diseases |
| D009140 | Musculoskeletal Diseases |
| D012216 | Rheumatic Diseases |
Not provided
Not provided
Single cohort of 27 individuals
Not provided
Not provided
This is a single-group study; therefore, no masking is possible.
Not provided
|
| Through study completion, which is anticipated to take approximately 1 year. |
| Clinically Important Improvement on ONE Functional Outcome Measure | The final component of the overall primary outcome of feasibility will be met if each participant achieves mean improvement on at least one functional outcome measure that exceeds the minimum clinically important difference. This may occur on a self-reported outcome measure (the KOOS, described below) or a performance-based outcome measure (30-second chair stand test, timed stair climb test, Timed Up and Go test, 40-meter fast-paced walk test, 6-minute walk test). All of these outcome measures are individually considered to be Secondary Outcome Measures and are described below in greater detail. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) |
Measures the number of seconds it takes the participant to climb and descend 1 full flight of standard stairs. |
| Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) |
| Functional outcome measure: Timed Up and Go (TUG) | Measures the number of seconds it takes for the participant to stand up from a chair, walk 3 meters, turn around, walk 3 meters back to the chair, and sit back down in the chair. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) |
| Functional outcome measure: 40-meter fast-paced walk test | Measures the number of seconds it takes the participant to walk 40 meters at what the participant considers to be a "fast pace". | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) |
| Functional outcome measure: 6-minute walk | Measures the number of meters the participant can walk in 6 minutes at a self-selected pace. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) |
| Functional outcome measure: Change from baseline in KOOS (Knee Injury and Osteoarthritis Outcome Score) to Post-Treatment | The KOOS is a self-reported survey containing five subscales, each of which is considered separately (i.e. there is no "total" KOOS score). The investigators will use three of the KOOS subscales: Pain (Minimum Detectable Change [MDC] 13.4 points for people with KOA), Activities of Daily Living (MDC 15.4 points), and Quality of Life (MDC 21.1 points). Each subscale is measured on a 0-100 scale, with lower scores indicating worse symptoms / worse function. | Baseline (measured at first visit) and post-treatment (measured at last visit, approximately 10 weeks later) |